Form 4: Edesa Biotech CEO Boosts Stake with Recent Share Purchases

Edesa Biotech's CEO and 10% owner, Pardeep Nijhawan, increased his beneficial ownership through direct purchases and a restricted share unit grant in late February and early March 2026.

Summary

• Pardeep Nijhawan, CEO, Director, and 10% Owner of Edesa Biotech, Inc. (EDSA), reported changes in his beneficial ownership.
• On February 26, 2026, Nijhawan directly acquired 20,571 common shares at a weighted average price of $1.5789 per share.
• On February 27, 2026, an entity wholly-owned by Nijhawan, Pardeep Nijhawan Medicine Professional Corporation, acquired 30,000 common shares at a weighted average price of $2.2232 per share.
• On March 2, 2026, Nijhawan directly received a grant of 10,016 restricted share units, which vested in full upon grant, under the Issuer's 2019 Equity Incentive Compensation Plan.
• Following these transactions, Nijhawan directly beneficially owns 625,813 common shares.
• Indirect beneficial ownership includes 371,702 shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 shares by The New Nijhawan Family Trust 2015, 32,013 shares by The Digestive Health Clinic Inc., and 53,104 shares by 1968160 Ontario Inc.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Significant insider buying by a CEO and 10% owner, combined with an RSU grant, typically indicates high confidence in the company's future performance and potential for share price appreciation.

Positives

• The CEO, Pardeep Nijhawan, increased his direct beneficial ownership by purchasing 20,571 common shares, signaling confidence in the company's future.
• An entity wholly-owned by the CEO also purchased an additional 30,000 common shares, further demonstrating insider commitment.
• The CEO received a grant of 10,016 restricted share units, which vested immediately, aligning management's interests with shareholders.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider ownership changes.

Industry Context

StockSavvy.ai notes that insider buying, particularly by a Chief Executive Officer and 10% owner, is often interpreted by the market as a strong signal of management's confidence in the company's future prospects and valuation. This action suggests that the CEO believes the company's shares are undervalued or expects positive developments.

Related Party Transactions

• Pardeep Nijhawan's indirect beneficial ownership includes shares held by Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., all of which are wholly-owned by the Reporting Person.
• Additional indirect beneficial ownership is held by The New Nijhawan Family Trust 2015, where Pardeep Nijhawan serves as a co-trustee.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management's belief in the company's value and future success, potentially boosting investor confidence.
• The grant of restricted share units further aligns the CEO's financial interests with those of other shareholders.

Key Dates

Recommendation

The significant increase in beneficial ownership by the CEO, Pardeep Nijhawan, through both direct purchases and a restricted share unit grant, signals strong insider confidence. This action by a key executive and 10% owner suggests a belief that the company's stock is currently undervalued or poised for positive developments, making it an attractive 'buy' signal for seasoned investors.

Keywords

Edesa Biotech, EDSA, Insider Trading, Beneficial Ownership, CEO, Stock Purchase, Restricted Share Units, Form 4